Business ❯Biotechnology
Drug Development Clinical Trials Stock Market Research and Development Job Loss Executive Changes Drug Development
The biotech company, once valued at $1.2 billion, has laid off 90% of its workforce and is exploring strategic options to preserve shareholder value.